So far more than 3,000 vials of the anti-SARS-CoV-2 immunoglobulin have been produced, Biomed Lublin CEO Marcin Pirog said, as cited in the Wednesday press release.
The drug made by fractionating the plasma of convalescent or asymptomatic COVID-19 survivors will now undergo clinical trials, the company said.
In vitro tests showed that the active substance contains, apart from specific antibodies, the so-called SARS-CoV-2 virus neutralising antibodies, Piotr Fic, the company's board member was quoted as saying.
"It should be noted that not all antibodies produced in the body of a person infected with the coronavirus neutralise the pathogen. The effectiveness of the fight against the virus is determined by neutralising antibodies, i.e. those that actively inhibit the so-called cytopathic effect (CPE) caused by the SARS-CoV-2 virus," the press release read.
Though the initial laboratory tests confirm the drug's effectiveness, clinical trials with patients are needed for registration. These will start in the fourth quarter of the year, according to Biomed Lublin. The drug's registration and commercialisation may take from a few to several months.
In the coming months, Poland could become the first country with a drug "successfully neutralising" COVID-19 if everything goes as planned, the press release read.(PAP)